In summary, SFXN4 is determined as an oncogene in HCC, SFXN4 may promote HCC development and progression via different mechanisms, indicating that SFXN4 may be a potential prognostic biomarker and therapeutic target in HCC. Here, SFXN4 is linked to hepatocellular carcinoma.